Medrysone

CHEMBL1201173 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
344.5 g/mol
LogP
2.7
Phase
4

A topical ophthalmic corticosteroid used as eye drops to treat inflammatory conditions of the eye including allergic conjunctivitis and other ocular inflammatory conditions. It has lower penetration into deeper eye tissues compared to other ophthalmic steroids.

Masse moléculaire

344,5000 g/mol

LogP

2,70

TPSA

54,40 Ų

Règle des 5 de Lipinski

Conforme

Mécanisme d'action

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C

InChI

InChI=1S/C22H32O3/c1-12-9-15-17-6-5-16(13(2)23)22(17,4)11-19(25)20(15)21(3)8-7-14(24)10-18(12)21/h10,12,15-17,19-20,25H,5-9,11H2,1-4H3/t12-,15-,16+,17-,19-,20+,21-,22+/m0/s1

Molecular Formula

C22H32O3

HBD / HBA

1 / 3

Liaisons Rotatives

1

Atomes Lourds

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A topical ophthalmic corticosteroid used as eye drops to treat inflammatory conditions of the eye including allergic conjunctivitis and other ocular inflammatory conditions. It has lower penetration into deeper eye tissues compared to other ophthalmic steroids.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Medrysone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201173. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 247839. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.